Last reviewed · How we verify
INBRX-106
At a glance
| Generic name | INBRX-106 |
|---|---|
| Also known as | Hexavalent OX40 agonist antibody |
| Sponsor | Providence Health & Services |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients (PHASE2)
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (PHASE1, PHASE2)
- INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (PHASE2, PHASE3)
- A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (PHASE2)
- A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (PHASE1)
- A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INBRX-106 CI brief — competitive landscape report
- INBRX-106 updates RSS · CI watch RSS
- Providence Health & Services portfolio CI